top of page
Search

FutureMeds Liverpool Named Global Site of the Year 2024 by the Company

  • Writer: FutureMeds
    FutureMeds
  • Jun 4
  • 2 min read

The award recognises consistent high performance during a year of rapid growth and operational complexity. 


FutureMeds Liverpool has been named Global Site of the Year 2024, in recognition of its consistent delivery, strong team culture, and measurable impact across multiple therapeutic areas. The award was announced by CEO Dr Radoslaw Janiak at the UK CEO Roadshow in Peebles, Scotland, last week. 


 Led by Site Director Angela Harnick, the Liverpool team maintained performance while scaling its capabilities, onboarding new staff, and managing a broad portfolio of trials. 


“I feel very lucky and proud to have a team who are very supportive and are always willing to rise to the challenge. We do what we say. We’re flexible, open and honest and we always offer a solution.”  

Angela Harnick, Site Director, FutureMeds Liverpool 

 


Consistent Delivery Across Key Indicators 


Throughout 2024, the Liverpool site expanded its therapeutic scope and supported multiple complex trials. It delivered strong results in Atherosclerotic Cardiovascular Disease (ASCVD), GLP-1 medications, vaccines, and addiction. 


In the GLP-1 therapeutic area, FutureMeds Liverpool’s performance contributed to a Sponsor decision to expand work across the FutureMeds network. The team also exceeded recruitment targets on several studies, maintained high retention and protocol adherence, and successfully completed its first sponsor audit with positive outcomes. 

  

These results were delivered during a period of rapid internal growth that required efficient onboarding of both permanent and temporary staff. 

 


Responding to Challenges 


In Q4 2024, the site faced a sharp increase in activity, creating temporary resource and space constraints. The team developed and executed a structured plan: responsibilities were clearly assigned, daily targets tracked, and training and quality oversight intensified. 


“It was a huge team effort. We measured progress daily, and we kept each other motivated by celebrating milestones together,” commented Angela Harnick. 


This disciplined yet collaborative approach enabled the team to stay on course, meet sponsor timelines, and maintain quality throughout a busy final quarter. 

 


Supporting People and Culture 


The site fosters a development-focused environment, aligning training with individual goals and reinforcing company values through day-to-day behaviours. Team culture is supported by collaboration with FutureMeds UK HR and the site’s culture captain to reinforce company values through everyday interactions. 


In addition to internal development, the team prioritises patient education and wellness in collaboration with local GPs and the NIHR, supporting broader trial accessibility and public health awareness. 


“At FutureMeds Liverpool we continue playing a key role in building sponsor confidence in FutureMeds' broader network. A very special thank you to the Liverpool team, whose support, passion and truth shine through in the work they do with patients and in the community every day.” 

Angela Harnick, Site Director, FutureMeds Liverpool 


FutureMeds Liverpool's team is raising the Global Site of the Year 2024 award
FutureMeds Liverpool's team is raising the Global Site of the Year 2024 award




Looking Ahead 


In 2025, the Liverpool team will continue expanding its capabilities. Priorities include completing a site refurbishment, finalising team structures, and building readiness for a new therapeutic area.

 

In parallel, the site will continue deepening relationships with local GPs and the NIHR to support patient education and increase trial access, while strengthening ties within the local community and vendor base. 

 
 
 

Bình luận


Bình luận về bài đăng này không còn nữa. Hãy liên hệ chủ trang web để biết thêm thông tin.
bottom of page